You just read:

Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

May 31, 2018, 12:31 ET